Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2016, Article ID 6087134, 8 pages
http://dx.doi.org/10.1155/2016/6087134
Research Article

Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality

1Harold Simmons Center for Kidney Disease Research and Epidemiology, School of Medicine, University of California, Irvine, Orange, CA, USA
2Division of Nephrology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea
3Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA
4Division of Nephrology and Hypertension, School of Medicine, University of California, Irvine, Orange, CA, USA

Received 3 December 2015; Accepted 6 April 2016

Academic Editor: Jochen Reiser

Copyright © 2016 Elani Streja et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Besarab, W. K. Bolton, J. K. Browne et al., “The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin,” The New England Journal of Medicine, vol. 339, no. 9, pp. 584–590, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. T. B. Drüeke, F. Locatelli, N. Clyne et al., “Normalization of hemoglobin level in patients with chronic kidney disease and anemia,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2071–2084, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. A. K. Singh, L. Szczech, K. L. Tang et al., “Correction of anemia with epoetin alfa in chronic kidney disease,” The New England Journal of Medicine, vol. 355, no. 20, pp. 2085–2098, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. A. Pfeffer, E. A. Burdmann, C.-Y. Chen et al., “A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease,” The New England Journal of Medicine, vol. 361, no. 21, pp. 2019–2032, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. B. D. Bradbury, M. A. Brookhart, W. C. Winkelmayer et al., “Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations,” American Journal of Kidney Diseases, vol. 54, no. 3, pp. 554–560, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Robins, M. Á. Hernán, and B. Brumback, “Marginal structural models and causal inference in epidemiology,” Epidemiology, vol. 11, no. 5, pp. 550–560, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. M. L. Petersen, S. G. Deeks, J. N. Martin, and M. J. van der Laan, “History-adjusted marginal structural models for estimating time-varying effect modification,” American Journal of Epidemiology, vol. 166, no. 9, pp. 985–993, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. A. Hernán and J. M. Robins, “Estimating causal effects from epidemiological data,” Journal of Epidemiology and Community Health, vol. 60, no. 7, pp. 578–586, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. O. Wang, R. D. Kilpatrick, C. W. Critchlow et al., “Relationship between epoetin alfa dose and mortality: findings from a marginal structural model,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 2, pp. 182–188, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. S. R. Cole and M. A. Hernán, “Constructing inverse probability weights for marginal structural models,” American Journal of Epidemiology, vol. 168, no. 6, pp. 656–664, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. FDA, “Drug safty communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease,” http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm.
  12. A. Shah, M. Z. Molnar, L. R. Lukowsky, J. J. Zaritsky, C. P. Kovesdy, and K. Kalantar-Zadeh, “Hemoglobin level and survival in hemodialysis patients with polycystic kidney disease and the role of administered erythropoietin,” American Journal of Hematology, vol. 87, no. 8, pp. 833–836, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Á. Hernán, B. Brumback, and J. M. Robins, “Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men,” Epidemiology, vol. 11, no. 5, pp. 561–570, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Zhang, M. Thamer, D. J. Cotter, J. Kaufman, and M. A. Hernán, “Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 3, pp. 638–644, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Zhang, M. Thamer, J. S. Kaufman, D. J. Cotter, and M. A. Hernán, “High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes,” Kidney International, vol. 80, no. 6, pp. 663–669, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. M. Suttorp, T. Hoekstra, M. Mittelman et al., “Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model,” Pharmacoepidemiology and Drug Safety, vol. 24, no. 10, pp. 1068–1075, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. A. J. Erslev, “Erythropoietin,” The New England Journal of Medicine, vol. 324, no. 19, pp. 1339–1344, 1991. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Fishbane and A. Besarab, “Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets,” Clinical Journal of the American Society of Nephrology, vol. 2, no. 6, pp. 1274–1282, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Wu, S. H. Lee, J. Gao, X. Liu, and M. L. Iruela-Arispe, “Inactivation of erythropoietin leads to defects in cardiac morphogenesis,” Development, vol. 126, no. 16, pp. 3597–3605, 1999. View at Google Scholar · View at Scopus
  20. A. Anagnostou, Z. Liu, M. Steiner et al., “Erythropoietin receptor mRNA expression in human endothelial cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 9, pp. 3974–3978, 1994. View at Publisher · View at Google Scholar · View at Scopus
  21. P. J. Stohlawetz, L. Dzirlo, N. Hergovich et al., “Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans,” Blood, vol. 95, no. 9, pp. 2983–2989, 2000. View at Google Scholar · View at Scopus
  22. E. Streja, C. P. Kovesdy, S. Greenland et al., “Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis,” American Journal of Kidney Diseases, vol. 52, no. 4, pp. 727–736, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. N. D. Vaziri, “Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency,” American Journal of Kidney Diseases, vol. 53, no. 5, pp. 733–736, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Lund, C. Lundby, and N. V. Olsen, “High-dose erythropoietin for tissue protection,” European Journal of Clinical Investigation, vol. 44, no. 12, pp. 1230–1238, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Koulouridis, M. Alfayez, T. A. Trikalinos, E. M. Balk, and B. L. Jaber, “Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis,” American Journal of Kidney Diseases, vol. 61, no. 1, pp. 44–56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Kalantar-Zadeh, G. H. Lee, J. E. Miller et al., “Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients,” American Journal of Kidney Diseases, vol. 53, no. 5, pp. 823–834, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. B. D. Bradbury, C. W. Critchlow, M. R. Weir, R. Stewart, M. Krishnan, and R. H. Hakim, “Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients,” Nephrology Dialysis Transplantation, vol. 24, no. 3, pp. 919–925, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. J. W. Adamson, “Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation,” Advances in Chronic Kidney Disease, vol. 16, no. 2, pp. 76–82, 2009. View at Publisher · View at Google Scholar · View at Scopus